Cannon, Christopher P.

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control

Ray, K. K., Ginsberg, H. N., Davidson, M. H., Pordy, R., Bessac, L., Minini, P., Eckel, R. H., & Cannon, C. P. (2016) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 127

Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB)

Cannon, C. P., McCabe, C. H., Stone, P. H., Schactman, M., Thompson, B., Theroux, P., Gibson, R. S., Feldman, T., Kleiman, N. S., Tofler, G. H., et al. (1997) · The American Journal of Cardiology

Acute Myocardial Infarction ResearchCircadian rhythm and melatonin

Cited by 122

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

Cannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J., Bakris, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., et al. (2020) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 117

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial

Ye, N., Jardine, M. J., Oshima, M., Hockham, C., Heerspink, H. J. L., Agarwal, R., Bakris, G., Schutte, A. E., Arnott, C., Chang, T. I., et al. (2021) · Circulation

Blood Pressure and Hypertension StudiesDiabetes Treatment and Management

Cited by 115

Results of a remotely delivered hypertension and lipid program in more than 10?000 patients across a diverse health care network.

Blood, A. J., Cannon, C. P., Gordon, W. J., Mailly, C., MacLean, T., Subramaniam, S., Tucci, M., Crossen, J., Nichols, H., Wagholikar, K. B., et al. (2023) · JAMA Cardiology

Telemedicine and Telehealth ImplementationBlood Pressure and Hypertension Studies

Cited by 108

An Invasive or Conservative Strategy in Patients With Diabetes Mellitus and Non–ST-Segment Elevation Acute Coronary Syndromes

O'Donoghue, M. L., Vaidya, A., Afsal, R., Alfredsson, J., Boden, W. E., Braunwald, E., Cannon, C. P., Clayton, T. C., de Winter, R. J., Fox, K. A. A., et al. (2012) · Journal of the American College of Cardiology

Coronary Interventions and DiagnosticsAcute Myocardial Infarction Research

Cited by 106

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease

Gotto, A. M., Cannon, C. P., Li, X. S., Vaidya, S., Kher, U., Brinton, E. A., Davidson, M., Moon, J. E., Shah, S., Dansky, H. M., et al. (2014) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 86

Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)

Murphy, S. A., Cannon, C. P., Wiviott, S. D., de Lemos, J. A., Blazing, M. A., McCabe, C. H., Califf, R. M., & Braunwald, E. (2007) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 82

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: pooled analysis of alirocumab phase 3 trials

Ray, K. K., Vallejo-Vaz, A. J., Ginsberg, H. N., Davidson, M. H., Louie, M. J., Bujas-Bobanovic, M., Minini, P., Eckel, R. H., & Cannon, C. P. (2019) · Atherosclerosis

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 69

Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial

Jarolim, P., White, W. B., Cannon, C. P., Gao, Q., & Morrow, D. A. (2018) · Diabetes Care

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 56

Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib

Davidson, M., Liu, S. X., Barter, P., Brinton, E. A., Cannon, C. P., Gotto, A. M., Leary, E. T., Shah, S., Stepanavage, M., Mitchel, Y., et al. (2013) · Journal of Lipid Research

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 56

Prescription of glucagon-like peptide-1 receptor agonists by cardiologists.

Vaduganathan, M., Patel, R. B., Singh, A., McCarthy, C. P., Qamar, A., Januzzi, J. L., Scirica, B. M., Butler, J., Cannon, C. P., & Bhatt, D. L. (2019) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 55

Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations

de Boer, I. H., Bakris, G., & Cannon, C. P. (2018) · JAMA

Blood Pressure and Hypertension StudiesClinical practice guidelines implementation

Cited by 54

Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial

Bhadriraju, S., Ray, K. K., DeFranco, A. C., Barber, K., Bhadriraju, P., Murphy, S. A., Morrow, D. A., McCabe, C. H., Gibson, C. M., Cannon, C. P., et al. (2006) · The American Journal of Cardiology

Hyperglycemia and glycemic control in critically ill and hospitalized patientsAcute Myocardial Infarction Research

Cited by 50

Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry

Meadows, T. A., Bhatt, D. L., Hirsch, A. T., Creager, M. A., Califf, R. M., Ohman, E. M., Cannon, C. P., Eagle, K. A., Alberts, M. J., Goto, S., et al. (2009) · American Heart Journal

Peripheral Artery Disease ManagementLipoproteins and Cardiovascular Health

Cited by 50

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

Wojeck, B. S., Inzucchi, S. E., Neeland, I. J., Mancuso, J. P., Frederich, R., Masiukiewicz, U., Cater, N. B., McGuire, D. K., Cannon, C. P., & Yaggi, H. K. (2023) · Sleep and Breathing

Diabetes Treatment and ManagementObstructive Sleep Apnea Research

Cited by 41

Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial

Barraclough, J. Y., Yu, J., Figtree, G. A., Perkovic, V., Heerspink, H. J. L., Neuen, B. L., Cannon, C. P., Mahaffey, K. W., Schutte, A. E., Neal, B., et al. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPeripheral Artery Disease Management

Cited by 37

Quality of Care and In-Hospital Outcomes in Patients With Coronary Heart Disease in Rural and Urban Hospitals (from Get With the Guidelines–Coronary Artery Disease Program)

Ambardekar, A. V., Fonarow, G. C., Dai, D., Peterson, E. D., Hernandez, A. F., Cannon, C. P., & Krantz, M. J. (2010) · The American Journal of Cardiology

Healthcare Quality and ManagementAcute Myocardial Infarction Research

Cited by 37

Racial differences in the management of unstable angina: Results from the multicenter GUARANTEE registry

Scirica, B. M., Moliterno, D. J., Every, N. R., Anderson, H. V., Aguirre, F. V., Granger, C. B., Lambrew, C. T., Rabbani, L. E., Sapp, S. K., Booth, J. E., et al. (1999) · American Heart Journal

Coronary Interventions and DiagnosticsCardiac Imaging and Diagnostics

Cited by 36

Remote Cardiovascular Hypertension Program Enhanced Blood Pressure Control During the COVID‐19 Pandemic

Lee, S. G., Blood, A. J., Cannon, C. P., Gordon, W. J., Nichols, H., Zelle, D., Scirica, B. M., & Fisher, N. D. L. (2023) · Journal of the American Heart Association

Telemedicine and Telehealth ImplementationBlood Pressure and Hypertension Studies

Cited by 33

Average Clinician‐Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial

White, W. B., Jalil, F., Cushman, W. C., Bakris, G. L., Bergenstal, R., Heller, S. R., Liu, Y., Mehta, C., Zannad, F., & Cannon, C. P. (2018) · Journal of the American Heart Association

Blood Pressure and Hypertension StudiesDiabetes Treatment and Management

Cited by 22

Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)

Pokharel, Y., Chinnakondepalli, K., Vilain, K., Wang, K., Mark, D. B., Davies, G., Blazing, M. A., Giugliano, R. P., Braunwald, E., Cannon, C. P., et al. (2017) · Circulation: Cardiovascular Quality and Outcomes

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 11

Systematic literature review on the real-world effectiveness and safety of bempedoic acid

Cicero, A. F. G., Cannon, C. P., Gautam, R., Anwar, S., Ghatak, A., Sarnes, E., Powell, H. A., Chhabra, R., & Jawla, S. (2026) · Atherosclerosis Plus

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 1